Member Info for Bainbo1

Jeez Alderboring 😴 same old rhetoric!!! copy, paste repeat.

Please do not state something is a fact unless you are absolutely certain….you just discredit yourself.

Key points:

• Approval comes from Estonian health authorities, not the FDA.

• The therapy can potentially be used before full regulatory approval.

• It may allow treatment of multiple patients and potential reimbursement through the Estonian National Health Fund. 

So the FDA does not control whether Estonia allows treatment.

These are facts….

I do think all IMO if you have to talk about a valuation on share price you need to raise the bar…….Remember not that long ago pre-clinical we were at 9p (£45) the excited talk was about the 50p party (£200) and the £1 party (£400)

We have a treatment that could potentially be revolutionary in its class, we await news on 3 surviving patients, news on cohort 4 and children treatment, news on Made producing at a greater speed, news on Estonia and working with Cellin and the Estonian government, potential news on a JV or complete buyout of Hemo, so just taking the lowest average on the buyout history at this early stage we could reasonably assume £1 billion this puts us at £165 a share, so much to look forward to with Hemo and no doubt a very exciting journey ahead for all shareholders.

NC Trade “ Registration of J.P.M Healthcare Conference is for clients of the firm, by invitation only.”

Whilst an invitation to the JPM Healthcare Conference raises awareness and gives Hemogenyx a platform to pitch to serious investors and raises exciting potential opportunities, we should be correct in stating this is not proof of an imminent non-dilutive investment or a formal client relationship with J.P. Morgan.

I feel the same way, I generally just ignore those like Alderbaran and Notforposting, having been invested in Hemo for 6 years I have seen many of them come and go, this rhetoric, with its continuous lies & distortion, is enough for me to push the button on my first ever bin on LSE.

No ramping, no hidden agenda just stating facts about the positive progress of this share.

1. DSMB Approval to Continue Phase I Trial & Start Pediatric Recruitment

Hemogenyx announced that its Data Safety Monitoring Board (DSMB) has approved the continuation of its Phase I clinical trial of their CAR-T therapy HG‑CT‑1 for relapsed/refractory acute myeloid leukemia (R/R AML).

This approval includes dose escalation and the start of pediatric enrolment.

Why it matters: This is a de-risking milestone. A DSMB approval suggests no major safety concerns so far, enabling the company to advance to higher doses and broaden the eligible patient population (to children/adolescents). That may accelerate progress and potentially improve the value proposition.

2. Letter of Intent (LOI) Signed for Commercialisation in Estonia

Hemogenyx signed an LOI with Cellin Technologies OÜ (an Estonian cell therapy company) to explore commercialization of HG-CT-1 via the “hospital exemption” pathway in Estonia.

Why it matters: This suggests Hemogenyx is preparing for early revenue pathways (outside of the traditional full regulatory approval route) — a hospital-exemption model could allow earlier patient access. It indicates strategic thinking about commercialisation rather than

3. Manufacturing Partnership Announced with Made Scientific

Hemogenyx revealed a manufacturing partnership with Made Scientific (a U.S.-based CDMO specialising in cell therapies) to support HG-CT-1 production.

Why it matters: Manufacturing cell therapies is highly complex. Partnering with an experienced contract development/manufacturing organisation reduces execution risk and may strengthen Hemogenyx’s ability to scale production and serve clinical/commercial demands

Hemogenyx published a schedule in October 2024 showing that the first clinical site for HG-CT-1 in adults was expected to get IRB approval by mid-November and the site initiation visit in the third week of November.

They announced in March 2025 that the first patient had been treated and passed initial safety.

In June 2025 they announced regulatory clearance (via the U.S. Food and Drug Administration) to proceed with a pediatric expansion of the Phase I trial.

In August 2025 they announced completion of the first adult dose cohort (third patient treated) and stated that, “pending no dose-limiting toxicities, Hemogenyx plans to advance to a second adult dose cohort at twice the initial dose, while simultaneously initiating recruitment for the pediatric arm.”

Hemogenyx has not yet moved into a large Phase II or Phase III “second trial” for HG-CT-1 — they are still in the Phase I adult dose escalation stage.

They must complete safety monitoring of the low-dose adult cohort, obtain DSMB clearance, then open higher dose cohort + pediatric arm.

The “delay” is likely just the normal pace of complex cell therapy development, rather than any unexpected hold-up.

Whilst the shareholders become impatient, we mustn’t forget Hemo & MDA have to build in a safety review period, Hemo have a manufacturing scale up to get to grips with, site initiation & regulatory site approval, all of this and more before committing to any timeline for next treatment.

The Phase 1 trial and release of information relating to it, has been timely and informative, lets us now exercise a little patience in allowing Hemo to ensure they are fully match fit for Phase 2 and Paediatric treatment.

If you see three or more of these in the next two quarters, it signals likelihood of a partnership or acquisition:

1. Positive higher-dose safety and early efficacy data

2. Regulatory designation (RMAT, Fast Track, or Orphan)

3. Manufacturing partnership or validated in-house capability

4. New IP or licensing filings around FLT3-CAR-T

5. Non-dilutive funding or strategic investor entry

This might be an AI generated response, however, we are already ticking some of those boxes, imo this quiet period on the public side doesn’t mean there is nothing happening behind the scenes,

Can trade on Halifax buy at 1169 sell at 1134

Here’s something to mull over, I asked AI possible buyout value based on positive stage 1 results with an initial early positive on stage2 and on paediatric: “If Hemogenyx shows sustained remissions and clean safety in both adult and paediatric AML, it could plausibly be valued in the $3–6 billion range before approval — and $7–10 billion+ if results translate into regulatory success or near-term commercialization”

We can only hope for the sake of those who need it most this continues to provide lifesaving results, if it does who knows where we could be in 6 months on a realistic value

@SocialistB Thanks for your response, it’s great to at last see and feel the positivity around Hemo, in support of your reply I asked Chat GPT what Hemo could be worth at current stage reply as follows:

For UK biotech firms with promising assets (either early clinical or strong preclinical with good translational potential), acquisition values tend to range from a few hundreds of millions up to around £1-2 billion, depending on how mature the asset is.

• Rare disease / unmet medical need / novel platforms often command higher valuations, because the market sees greater upside / less competition.

• Acquisitions in the CAR-T / cell therapy / immunotherapy / platform tech space seem to carry premiums, especially if the technology is differentiated or enables new modes of administering therapy.

I asked if share price is £12 and Mcap of £67 million and company were sold for £1 billion, what would the share price be?

share price ≈ £179.10 per share — about a 1,392% increase from £12.

Considering we had a 635% increase in one month this is clearly very achievable.

Exciting times for all genuine investors

@HFH thanks for the info please keep your thoughts coupled with the facts coming, I have been in Hemo for 5+ years and lived the lows hopefully now going to be living plenty of highs, on that note I recall excitement when we reached in old money 15p at today’s conversion £60, there was then talk of easily making 25p and 50p and let’s not forget the £1 party invites flying around. My point is whilst Hemo HCT1 continues to succeed which is truly amazing and VS continues to get his ducks in a row, based on past history and expectations, I would like to think your £50 and £100 share estimates are on the low side, what are your thoughts and any other genuine LTH’s thoughts on realistic and achievable SP value based on continued success and development.

@ Alderbaran there is a very interesting program on UK TV which is a game of mind manipulation based on casting doubt and uncertainty in the minds of others at the same time portraying yourself as the shining guiding light, the one person who above all others should be believed by all in what they say.

“The Traitors” is the shows title, it’s the traitors who try and cast doubt and fear in the minds of others, your position on Hemo from historical posts on this site is abundantly clear, the unfortunate truth for you is, you have been identified as a traitor and like all traitors you have been found out and voted out, your time here is done the vote is cast, Alderbaran exit stage left!!

GO HEMO GO!!

Interesting response from AI on the question of “Have Hemo having found a cure for AML”

Whilst we are still waiting confirmation of the results of P1,2&3, it is through a lack of any negative RNS since these cohorts were given treatment, that a fairly reasonable inference could be drawn of the success thus far.

It is impossible to give a precise valuation for Hemogenyx Pharmaceuticals, but a "cure" for Acute Myeloid Leukemia (AML) would likely catapult the company's valuation into the multi-billion dollar range, far exceeding its current market capitalization, due to the transformative nature of such a breakthrough. A definitive valuation would depend on factors like the market size for the cure, regulatory approval timelines, the number of patients who could benefit, and the competitive landscape for existing and emerging AML treatment.

Focus on the sentence “Multi Billion Dollar range” certainly paints a more promising picture for all potential and current investors.

Surely if you had a fireworks news to release you would drop the RNS at the beginning of the week to give the SP the full benefit of the news.

@saint & socialist I am basing this on figures available and rudimentary calculations on a £1billion sale, not meant to mislead anyone, there may well be a formula I’m not aware of to calculate value, sure we have people on here with far more expertise on how to calculate share value, I would be pleased to hear from them. 👍

As at 14 May 2025, the number of shares in issue was 4,343,539, the remainder are unissued shares, total number of shares available are according to online research 8.6 million.

When you look at the deals reported by Oldrig it seems anything upwards of £1billion is realistic, if Hemo continues with the perceived success following on from P1&P2 (assumptions are made as we don’t know the effficey results) then with 4.7 million shares in circulation (this may increase with further sales by the BOD on the loophole they have discovered) then the average share price value would be £212.38 per share, if all available shares are in circulation 8.6million the share price on a £1billion sale would equate to £116.27 per share.

This is not a ramp simply answering a question to what the share price could be on selling for £1billion. All figures are approximate and ball park and IMO.

There was a time not that long ago when the chat on here talked about the £1 share party, (£400 since conversion) so yes that might have been a fantasy period, however, we now have AI valuations based on fact of current Hemo status, (not the usual made up fiction we see on here) putting Hemo on a conservative valuation of £150 million 21 times the current valuation of £7 million, still nowhere near the £1 (£400) but looking at a recent Pharmaceutical buy in this arena, the 0.50p (£200) a share party is very achievable and realistic IMO.